Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans

Biotechnology and Bioengineering

Volumn 111, Issue 10, 2014, Pages 1907-1919

  Shi, Helen H ^a   Goudar, Chetan T ^a  

^a AMGEN INC   (United States)

Author keywords

High mannose; Mammalian cell culture; Protein glycosylation; Therapeutic antibodies

Indexed keywords

ESTERIFICATION; GENETIC ENGINEERING; GLYCOSYLATION; MONOCLONAL ANTIBODIES; POLYSACCHARIDES;

BIOLOGICAL IMPLICATIONS; BIOPHARMACEUTICAL INDUSTRY; CHINESE HAMSTER OVARY CELLS; HIGH MANNOSE; MAMMALIAN CELL CULTURE; PROTEIN GLYCOSYLATION; THERAPEUTIC ANTIBODIES; THERAPEUTIC MONOCLONAL ANTIBODIES;

CELL CULTURE;

ALPHA GLUCOSIDASE; ALPHA MANNOSIDASE; DOLICHOL PHOSPHATE; GLUCOSE; GLUTAMINE; GLYCAN DERIVATIVE; KIFUNENSINE; MANNOSE; MANNOSIDASE INHIBITOR; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINYLTRANSFERASE; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE; GLYCOPROTEIN; POLYSACCHARIDE;

ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; BIOLOGICAL ACTIVITY; CELL VIABILITY; CHEMICAL MUTAGENESIS; CHO CELL LINE; ENZYME GLYCOSYLATION; GENETIC ENGINEERING; GENETIC MANIPULATION; HUMAN; IMMUNOGENICITY; MAMMAL CELL; MODULATION; NONHUMAN; PROTEIN GLYCOSYLATION; REVIEW; TRANS GOLGI NETWORK; ANIMAL; BIOTECHNOLOGY; CARBOHYDRATE ANALYSIS; CELL ENGINEERING; CHEMISTRY; CRICETULUS; CULTURE TECHNIQUE; GENETICS; GLYCOSYLATION; HAMSTER; METABOLISM; MOLECULAR GENETICS; PROCEDURES;

CRICETULUS GRISEUS; MAMMALIA;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; CARBOHYDRATE SEQUENCE; CELL CULTURE TECHNIQUES; CELL ENGINEERING; CHO CELLS; CRICETINAE; CRICETULUS; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; MANNOSE; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES;

EID: 84906780136     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25318     Document Type: Review

References (44)

1. Aggarwal SR. 2014. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol 32(1):32-39.
2. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 25:21-50.
3. Awwad M, Strome PG, Gilman SC, Axelrod HR. 1994. Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions. Cancer Immunol Immunother 38(1):23-30.
4. Brown JR, Crawford BE, Esko JD. 2007. Glycan antagonists and inhibitors: A fount for drug discovery. Crit Rev Biochem Mol Biol 42(6):481-515.
5. Camire J. 2000. Chinese hamster ovary cells for the production of recombinant glycoproteins. Art Sci 19(1):150-151.
6. Chen W, Stanley P. 2003. Five Lec1 CHO cell mutants have distinct Mgat1 gene mutations that encode truncated N-acetylglucosaminyltransferase I. Glycobiology 13(1):43-50.
7. Chen X, Liu YD, Flynn GC. 2009. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 19(3):240-249.
8. Elbein AD. 1984. Inhibitors of the biosynthesis and processing of N-linked oligosaccharides. CRC Crit Rev Biochem 16(1):21-49.
9. Elbein AD. 1991. Glycosidase inhibitors: Inhibitors of N-linked oligosaccharide processing. FASEB J 5(15):3055-3063.
10. Elbein AD, Tropea JE, Mitchell M, Kaushal GP. 1990. Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I. J Biol Chem 265(26):15599-15605.
11. Fuhrmann U, Bause E, Legler G, Ploegh H. 1984. Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides. Nature 307(5953):755-758.
12. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. 2011. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21(7):949-959.
13. Gross V, Tran-Thi TA, Schwarz RT, Elbein AD, Decker K, Heinrich PC. 1986. Different effects of the glucosidase inhibitors 1-deoxynojirimycin, N-methyl-1-deoxynojirimycin and castanospermine on the glycosylation of rat alpha 1-proteinase inhibitor and alpha 1-acid glycoprotein. Biochem J 236(3):853-860.
14. Harris LJ, Skaletsky E, McPherson A. 1998. Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol 275(5):861-872.
15. Hills AE, Patel A, Boyd P, James DC. 2001. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells. Biotechnol Bioeng 75(2):239-251.
16. Hossler P, Khattak SF, Li ZJ. 2009. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19(9):936-949.
17. Jefferis R. 2009. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8(3):226-234.
18. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M. 2007. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 17(1):104-118.
19. Kaufman RJ, Swaroop M, Murtha-Riel P. 1994. Depletion of manganese within the secretory pathway inhibits O-linked glycosylation in mammalian cells. Biochemistry 33(33):9813-9819.
20. Kornfeld R, Kornfeld S. 1985. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54:631-664.
21. Long CG, Simonson RB, Ultee ME, Gillette RW. 1988. Suppression of oligosaccharide side chain trimming yields monoclonal antibodies with greater capacity for site specific labeling. ICSU Short Rep 8:179.
22. Mimura Y, Jefferis R, Mimura-Kimura Y, Abrahams J, Rudd PM. 2009. Glycosylation of therapeutic antibodies. In: An Z, editor. Therapeutic monoclonal antibodies: From bench to clinic. Hoboken, NJ: John Wiley & Sons, Inc. p 67-89.
23. Pacis E, Yu M, Autsen J, Bayer R, Li F. 2011. Effects of cell culture conditions on antibody N-linked glycosylation-what affects high mannose 5 glycoform. Biotechnol Bioeng 108(10):2348-2358.
24. Palamarczyk G, Mitchell M, Smith PW, Fleet GW, Elbein AD. 1985. 1, 4-Dideoxy-1, 4-imino-D-mannitol inhibits glycoprotein processing and mannosidase. Arch Biochem Biophys 243(1):35-45.
25. Pan YT, Elbein AD. 1982. The formation of lipid-linked oligosaccharides in Madin-Darby canine kidney cells. Changes in oligosaccharide profiles induced by glucosamine. J Biol Chem 257(6):2795-2801.
26. Robinson DK, Chan CP, Yu Lp C, Tsai PK, Tung J, Seamans TC, Lenny AB, Lee DK, Irwin J, Silberklang M. 1994. Characterization of a recombinant antibody produced in the course of a high yield fed-batch process. Biotechnol Bioeng 44(6):727-735.
27. Rose DR. 2012. Structure, mechanism and inhibition of Golgi alpha-mannosidase II. Curr Opin Struct Biol 22(5):558-562.
28. Rothman RJ, Perussia B, Herlyn D, Warren L. 1989. Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation. Mol Immunol 26(12):1113-1123.
29. Sealover NR, Davis AM, Brooks JK, George HJ, Kayser KJ, Lin N. 2013. Engineering Chinese hamster ovary (CHO) cells for producing recombinant proteins with simple glycoforms by zinc-finger nuclease (ZFN)-mediated gene knockout of mannosyl (alpha-1, 3-)-glycoprotein beta-1, 2-N-acetylglucosaminyltransferase (Mgat1). J Biotechnol 167(1):24-32.
30. Spearman M, Dionne B, Butler M. 2011. The role of glycosylation in therapeutic antibodies. In: Al-Rubeai M, editor. Antibody expression and production. Dordrecht, Netherlands: Springer Science+Business Media. p 251-292.
31. Stanley P. 1983. Lectin-resistant CHO cells: Selection of new mutant phenotypes. Somatic Cell Genet 9(5):593-608.
32. Stanley P, Caillibot V, Siminovitch L. 1975a. Selection and characterization of eight phenotypically distinct lines of lectin-resistant Chinese hamster ovary cell. Cell 6(2):121-128.
33. Stanley P, Narasimhan S, Siminovitch L, Schachter H. 1975b. Chinese hamster ovary cells selected for resistance to the cytotoxicity of phytohemagglutinin are deficient in a UDP-N-acetylglucosamine-glycoprotein N-acetylglucosaminyltransferase activity. Proc Natl Acad Sci USA 72(9):3323-3327.
34. Stanley P, Schachter H, Taniguchi N. 2009. N-Glycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials of glycobiology. 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
35. Strohl WR. 2009. Therapeutic monoclonal antibodies: Past, present, and future. In: An Z, editor. Therapeutic monoclonal antibodies: From bench to clinic. Hoboken, NJ: John Wiley & Sons, Inc. p 3-50.
36. van Berkel PH, Gerritsen J, van Voskuilen E, Perdok G, Vink T, van de Winkel JG, Parren PW. 2010. Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system. Biotechnol Bioeng 105(2):350-357.
37. Varki A, Esko JD, Colley KJ. 2009. Cellular organization of glycosylation. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials of glycobiology. 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
38. Varki A, Sharon N. 2009. Historical background and overview. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials of glycobiology. 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
39. Wong DCF, Wong KTK, Goh LT, Heng CK, Yap MGS. 2005. Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. Biotechnol Bioeng 89(2):164-177.
40. Wright A, Morrison SL. 1994. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 180(3):1087-1096.
41. Wright A, Sato Y, Okada T, Chang K, Endo T, Morrison S. 2000. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 10(12):1347-1355.
42. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R. 2012. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs 4(4):475-487.
43. Zhong X, Cooley C, Seth N, Juo ZS, Presman E, Resendes N, Kumar R, Allen M, Mosyak L, Stahl M, et al. 2012. Engineering novel Lec1 glycosylation mutants in CHO-DUKX cells: Molecular insights and effector modulation of N-acetylglucosaminyltransferase I. Biotechnol Bioeng 109(7):1723-1734.
44. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T. 2008. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99(3):652-665.